Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Trading 06-11 13:35:27 EDT

442.67

+3.63

+0.83%

High445.76	Low431.92	Vol6.73M
Open438.91	D1 Closing439.04	Amplitude3.15%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O108.88M	T/O Rate--	Tradable Shares0.00
P/B2.831519	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":442.66724,"timestamp":1781199326322,"preClose":439.03735,"halted":0,"volume":6732300,"delay":0,"changeRate":0.008268,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":3.629883,"latestTime":"06-11 13:35:27 EDT","open":438.913,"high":445.76224,"low":431.91968,"amount":108878042.399936,"amplitude":0.031529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781208000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.831519,"peRate":-8.96765,"turnoverRate":0.014389,"increases":3,"decrements":1,"flats":0,"marketCap":9967573248,"floatMarketCap":9316241664},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2642407776","title":"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642407776?lang=en_us&edition=fundamental","pubTime":"2026-06-11 16:31","pubTimestamp":1781166709,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNG...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-crispr-therapeutics-ag-crsp-and-hinge-health-inc-class-a-hnge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-crispr-therapeutics-ag-crsp-and-hinge-health-inc-class-a-hnge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4611","CRSP","HNGE","BK4196","LU0128526141.USD","BK4210","BK4137","LABU","BK4581","LU1861559042.SGD","BK4585","BK4588","LU1861558580.USD","BK4556","HCSG","XBI","AG","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642647666","title":"Intellia Therapeutics shareholders elect Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642647666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642647666?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:36","pubTimestamp":1781123815,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics held its annual shareholder meeting on June 9, 2026.Shareholders backed the election of Muna Bhanji, Brian Goff, Jesse Goodman as directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL4MkdMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861559042.SGD","BK4535","BK4139","BK4556","BK4585","NTLA","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642943604","title":"A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2642943604","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642943604?lang=en_us&edition=fundamental","pubTime":"2026-06-10 01:30","pubTimestamp":1781026252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) is back in focus after reporting strong Phase 3 data for lonvoguran ziclumeran in hereditary angioedema, outlining regulatory submission plans, and pairing the update with an upsized equity raise.\nSee our latest analysis for Intellia Therapeutics.\nDespite a modest 1-day share price decline of 0.37% to US$13.49 and a softer 30-day share price return of 4.26% down, the year-to-date share price return of 46.47% and 1-year total shareholder return of 62.92% suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-after-phase-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EQR","IE0034390439.USD","LU0012050646.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0106261612.USD","LU1169589451.USD","NTLA","LU1861558580.USD","BK4585","LU0205193047.USD","LU1861559042.SGD","BK4215","BK4198","IE00B64QTZ34.USD","BK4139","BK4556","IE00B19Z6F94.USD","BK4588","LU1169590202.USD","BK4535","HAE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642027434","title":"Beam Stockholders Back Board, Leadership at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642027434","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642027434?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:06","pubTimestamp":1780952811,"startTime":"0","endTime":"0","summary":"An update from Beam Therapeutics ( ($BEAM) ) is now available. At its annual meeting of stockholders held on June 3, 2026, Beam Therapeutics Inc. r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beam-stockholders-back-board-leadership-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beam-stockholders-back-board-leadership-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","LU1861559042.SGD","BK4611","BK4588","LU1861558580.USD","BK4505","BK4535","BK4556","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642431596","title":"Beam Therapeutics shareholders elect Class III directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642431596","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642431596?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:06","pubTimestamp":1780949198,"startTime":"0","endTime":"0","summary":"Beam Therapeutics held its annual shareholder meeting on June 3, 2026.Shareholders backed the board’s director slate, with all nominees receiving sufficient support.Deloitte & Touche was ratified as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL4gZ4yx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BEAM","BK4139","BK4588","BK4556","BK4585","LU1861558580.USD","BK4535","BK4611","LU1861559042.SGD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481979","title":"Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481979","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481979?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:05","pubTimestamp":1780920300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA5Q1HFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMO","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641176978","title":"Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2641176978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641176978?lang=en_us&edition=fundamental","pubTime":"2026-06-07 21:31","pubTimestamp":1780839063,"startTime":"0","endTime":"0","summary":"In early June 2026, CRISPR Therapeutics AG filed a shelf registration for up to US$969.16 million in common shares linked to its employee stock plans, shortly after shareholders approved amendments to the company’s articles of association at the annual meeting. \nComing on the heels of high-profile conference presentations and growing attention to its Casgevy launch and cardiovascular gene-editing pipeline, these corporate moves highlight how CRISPR Therapeutics is building financial and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/why-crispr-therapeutics-crsp-is-down-77-after-major-shelf-fi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/why-crispr-therapeutics-crsp-is-down-77-after-major-shelf-fi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","BK4585","BK4556","BK4139","BK4588","CRSP","LU1861559042.SGD","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641472371","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641472371","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641472371?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:05","pubTimestamp":1780689900,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June  05, 2026  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/05/3307600/0/en/Intellia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","NTLA","BK4585","BK4556","BK4588","LU1861558580.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641198649","title":"Shareholders Approve New Incentive Plan and Governance Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2641198649","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641198649?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:52","pubTimestamp":1780613573,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG ( ($CRSP) ) has provided an update. On June 4, 2026, CRISPR Therapeutics shareholders approved a new 2026 Stock Option and I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shareholders-approve-new-incentive-plan-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shareholders-approve-new-incentive-plan-and-governance-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4611","LU1861558580.USD","BK4139","CRSP","BK4556","BK4585","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641167608","title":"CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2641167608","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641167608?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:46","pubTimestamp":1780605977,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics held its annual general meeting on June 4, 2026.Shareholders adopted the 2026 Stock Option and Incentive Plan, authorizing awards such as options, stock appreciation rights, restricted stock, and RSUs.Amendments to the articles of association were adopted; effectiveness was tied to subsequent registration and approvals, not confirmed as completed.Shareholders endorsed the 2025 Swiss management report, consolidated financial statements, statutory financial statements, and the carryforward of the net loss.Auditors were reappointed; the independent voting rights representative was reappointed; an expanded capital band and higher conditional share capital for bond conversions were authorized.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL4TXjlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4585","BK4556","BK4139","BK4588","CRSP","LU1861559042.SGD","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640159863","title":"Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640159863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640159863?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:00","pubTimestamp":1780567243,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD) and Crispr Therapeutics AG (CRSP) wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insulet-podd-crispr-therapeutics-ag-crsp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insulet-podd-crispr-therapeutics-ag-crsp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU2065169927.USD","BK4139","LU1861558580.USD","LU2065170008.USD","LU1084165304.USD","BK4551","LU1861559042.SGD","BK4082","BK4566","LU1119994496.HKD","CRSP","BK4556","PODD","LU0728928796.USD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","BK4611","BK4585","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640562829","title":"Intellia to present additional Phase 3 HAELO data for lonvo-z in hereditary angioedema at EAACI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640562829","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640562829?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:31","pubTimestamp":1780313482,"startTime":"0","endTime":"0","summary":"Intellia flagged additional Phase 3 HAELO data for lonvo-z in hereditary angioedema for a late-breaking oral presentation at EAACI 2026.The results have not been presented yet; the readout is scheduled for June 13, 2026.The update is positioned as a key clinical milestone for the CRISPR-based program as it advances toward potential commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5Xmdw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","LU1861559042.SGD","BK4535","LU1861558580.USD","BK4556","NTLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959336","title":"Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959336","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959336?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June  01, 2026  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304241/0/en/Intellia-Therapeutics-to-Report-Additional-Phase-3-HAELO-Data-for-Lonvoguran-Ziclumeran-lonvo-z-in-Late-Breaking-Oral-Presentation-at-EAACI-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","IE00B64QTZ34.USD","BK4183","NTLA","LU0012050646.USD","LU1169589451.USD","LU0205194284.USD","ODD","LU1861559042.SGD","HAE","BK4588","CRSP","IE0034390439.USD","BK4585","BK4535","IE00BLDYK493.USD","BK4556","LU0205193047.USD","BK4198","LU1861558580.USD","BK4611","LU0106261612.USD","LU1169590202.USD","IE0009354923.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639205620","title":"Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift","url":"https://stock-news.laohu8.com/highlight/detail?id=2639205620","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639205620?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:08","pubTimestamp":1780056536,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics recently reported positive phase III results for its CRISPR therapy lonvoguran ziclumeran in hereditary angioedema and began a rolling BLA submission to the FDA, while the FDA also lifted clinical holds on its other phase III candidate, nexiguran ziclumeran, allowing those trials to resume.\nThese twin milestones not only move Intellia’s in vivo CRISPR programs closer to potential commercialization but also reduce clinical and regulatory uncertainty around its most...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-up-106-after-crispr-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-up-106-after-crispr-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861559042.SGD","BK4611","BK4588","III","LU1861558580.USD","BK4134","BK4535","AIPO","BK4556","CRSP","BK4139","NTLA","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661684","title":"Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661684","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661684?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:01","pubTimestamp":1779998460,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303236/0/en/Editas-Medicine-Announces-Updated-Presentation-Time-for-Upcoming-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638448698","title":"CRISPR Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638448698","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638448698?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, May  28, 2026  (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the follow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302788/0/en/CRISPR-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU1861559042.SGD","BK4588","BK4585","LU1861558580.USD","BK4139","CRSP","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768210","title":"Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768210","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768210?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:33","pubTimestamp":1779899629,"startTime":"0","endTime":"0","summary":"After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the Eu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638569682","title":"TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’","url":"https://stock-news.laohu8.com/highlight/detail?id=2638569682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638569682?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:16","pubTimestamp":1779898611,"startTime":"0","endTime":"0","summary":"TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in low-density lipopro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-cowen-remains-bullish-on-editas-medicine-after-compelling-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-cowen-remains-bullish-on-editas-medicine-after-compelling-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","EDIT","COWN","TD","BK4556","BK4585","BK4127","BK4139","BK4207"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction